Revolutionary smart devices for skin biophysiology

See the warning.
Stop the wound.

Wireless, AI-driven sensors that protect skin under every cast or splint — and over at-risk soft tissue from head to toe. Built to warn care teams before a pressure injury ever forms.

Explore the products See EMR integration
Loose
Optimal
Issue
At-a-glance status, on-cast & in-app
A person resting at home with a CastLiner™ smart cast on the forearm; an inset phone shows the companion app, with on-cast LED status indicators for Optimal, Issue, and Loose fit.
Built for the bedside
Operating room ICU & acute care Orthopedics & casting Extended & home care

The science behind our approach

Skin is the body's largest organ.

It is the first indicator of every physiological event — detecting change before traditional monitoring catches it. We build the smart devices that read it.

The hidden epidemic

Pressure injuries are among the most costly preventable harms in healthcare.

They develop where clinicians can't easily see or feel — under casts, splints, and dressings, and over bony, high-risk areas. By the time damage is visible, intervention is already late.

1 / 38 sec
A cast or splint is applied roughly every 38 seconds in U.S. emergency and ambulatory settings — about 1.5 million a year.1
10–28%
Of those applications develop complications — driving over $300 million in secondary U.S. healthcare costs.1
32 mmHg
Sustained pressure above ~32 mmHg for as little as 2 hours can trigger tissue ischemia — often under a cast, where no one can see or feel it.1

What's counted vs. what's actually happening

Hospital-acquired pressure injuries — what DermaLiner™ is built to catch early over high-risk skin — are among the most under-counted harms in medicine. Active chart-review studies have found that official records capture only a small fraction of what actually occurs.6

Officially reported
2.5M
U.S. hospital pressure injuries recorded each year
~$26.8B
commonly cited annual U.S. cost
≈20×
Administrative data has been found to capture only ~5% of injuries identified on active chart review
Estimated true incidence
~50M
cases identified through active chart-review surveillance
$500B+
estimated true annual economic burden

Device-related injuries — those forming under casts, splints, and compression devices — account for an estimated 30–34.5% of all hospital-acquired pressure injuries, and are the hardest of all to see until the damage is already done.6

Figures reflect published clinical literature and are provided for context (in pediatrics, complications rise to roughly 8.9 per 1,000 applications, and ~17.9 per 1,000 when the heel is involved). The reported-vs-estimated pressure-injury counts and costs above reflect active chart-review surveillance studies, which report substantially higher rates than administrative data; estimated true-incidence and economic-burden figures are derived by applying published under-reporting multipliers and vary by population and method. These describe the clinical problem fiomet's technology is designed to help address, not a guaranteed outcome of any fiomet product.

Two devices, one platform

Continuous pressure protection — wherever the risk is.

The same sensing platform, packaged for two clinical settings. Both pair with a detachable LED module, a companion app, and EMR integration.

A hand holding the thin, transparent CastLiner™ cut-to-fit sensor strip with its sensing zones and detachable module connector
Under casts & splints
LED moduleCastLiner™ detachable LED module showing live pressure status

CastLiner™

Cut-to-fit sensor strip · placed under the cast or splint

A thin, flexible sensor strip that sits discreetly beneath casts, splints, and wraps — giving real-time pressure feedback during application and through the critical early hours of immobilization, so issues are caught before skin is damaged.

  • Real-time feedback helps clinicians apply casts at controlled, consistent pressure
  • On-cast LED module shows status at a glance — no phone required
  • Cut-to-fit along marked lines for forearm, calf, heel, and more
DermaLiner™ over high-risk skin
Over high-risk skin

DermaLiner™

Tegaderm-based adhesive strip · placed over the skin

An ultra-thin, conformable adhesive sensor for high-risk areas — heel, sacrum, elbow, hip, back of head, and ear — for hospital, outpatient, and extended-care monitoring.

  • Anatomically conforms to bony, pressure-prone areas
  • Continuous, non-invasive monitoring without wires or frequent manual checks
  • Multi-contact sensing designed for neuro / ICU monitoring use cases
How it works

From application to early intervention — in five steps.

Apply the sensor to the limb1

Apply

Place the sensor on any region where pressure is a concern.

Observe live pressure in the app2

Observe

Watch real-time pressure as the cast or dressing is placed. Green denotes acceptable ranges.

Alert on a change in baseline pressure3

Alert

Get notified when baseline pressure shifts toward a possible adverse event.

Adjust the cast where pressure is too high4

Adjust

Relieve areas flagged in red before tissue damage can develop.

Send data to the cloud and EMR5

Send

Stream data to the cloud and EMR to track pressure trends over time.

See it in action

Watch CastLiner™ work — from strip to live reading.

A walkthrough of the sensor strip, the detachable LED module, and the companion app showing live, per-zone pressure.

App showing blue, too-loose pressure state
Blue — too looseCast or splint may be unstable.
App showing green, optimal pressure state
Green — optimalWithin the clinician-set range.
App showing red, high-pressure calibration state
Red — risky pressureAbove threshold — evaluate.

Per the Instructions for Use, the on-device LED is the primary indicator and remains visible regardless of phone or Bluetooth status; the app is a companion display. CastLiner™ is a monitoring aid and does not replace routine skin assessment or clinical judgment.

The technology

Sensors, signal, and AI working together.

A patented sensor system feeds a proprietary AI engine trained on fiomet's own pressure datasets — designed to tell harmful pressure apart from normal movement.

30,000data points / min
Inside the companion app
Live per-zone readings
Companion-app Segments view: each dot is a 30-second pressure segment read left to right; early segments are green and they progress through yellow and orange to red, with a sustained-high-pressure alert
Recorded over time — pressure heat-map

Patented sensor & smart module

A flexible, cut-to-fit strip tracks pressure continuously and surfaces status on a detachable, rechargeable LED module.

Proprietary AI engine

Trained on fiomet's pressure datasets to distinguish harmful pressure-related changes from everyday muscle movement and activity.

Proprietary datasets

Skin-pressure and bio-change data captured through fiomet's own sensors — the foundation the models are built on.

from 10 mmHgSenses pressure from as low as ~10 mmHg — below the ~50 mmHg floor of typical off-the-shelf sensors.1
under 1 mmThin, flexible, and fully wireless — conductive inks replace wires, so the sensor adds no pressure of its own.1
antimicrobialBacteriostatic silver-ink traces, latex-free, with a gentle skin-tolerant adhesive for intact skin.4
Artificial intelligence

AI-powered wound prevention.

Detect and prevent pressure injuries before they occur. Not monitoring — interception.

Live tissue-stress map — red marks where pressure is trending toward harm.

We are a data and AI company.

fiomet is — as far as we know — the only company able to monitor and collect live skin-pressure and bio-change data, then turn it into prediction. Our AI reads live tissue-stress signals: a dataset no other company collects or can replicate.

Wireless skin sensors Physiologic AI processing Predictive AI engine Clinician intervention
Two time-series graphs: the left labeled 30,000 data points per minute, the right showing the AI model predicting a muscle cramp and fatigue event in real time.
Collecting ~30,000 data points per minute — feeding an AI model trained to flag negative events in real time.1
Fits your workflow

Integrates with the EMR your teams already use.

CastLiner™ pressure appears on the patient's vitals flowsheet like any other vital sign — heart rate, blood pressure, respirations — inside platforms your teams already use, such as Epic. Because it lives in the existing chart, it needs no new hospital systems or added staff, and it isn't a separate, stand-alone readout the care team has to interpret on its own.

Epic Hyperspace anesthesia intraprocedure record showing CastLiner™ cast pressure tracked beside heart rate, NIBP, SpO2 and respirations, with live dorsal, plantar and lateral monitoring rows
In the OR — live CastLiner™ pressure on the Epic anesthesia record, tracked beside heart rate, NIBP, SpO₂ and respirations.
Epic patient chart overview with CastLiner™ dorsal, plantar and lateral cast pressures listed on the vitals page next to BP, HR, RR, SpO2, temperature and pain, plus a continuous pre-op to post-op pressure timeline
On the floor — cast pressure on the vitals page beside BP, HR, RR and SpO₂, with a continuous pre-op → post-op timeline.
A forearm with a live sensor mesh and a vitals-style pressure waveform beneath it
On the chart it reads as a continuous, vitals-style waveform — just like any other monitored vital.

  • Charts like any other vital

    Dorsal, plantar, and lateral pressures display on the vitals flowsheet right next to heart rate, blood pressure, and respirations.

  • No added hospital resources

    It surfaces inside the EMR teams already run — nothing extra to deploy, license, or staff to make it work.

  • No separate result to interpret

    Pressure reads as a standard vital on the existing chart — not a new, stand-alone readout the team is asked to interpret on its own.

  • Real-time, remote-ready & RPM-eligible

    Notifies the hospital and patient when pressure shifts, on-site or after discharge — and is designed to support RPM workflows and their CPT billing codes.5

CPT 994539945499457 9945899091

CPT codes shown for reference. Coverage, eligibility, and reimbursement vary by payer and clinical circumstance; verify independently. CPT® is a registered trademark of the American Medical Association.

Evidence & research

Validated on the bench, in large animals, and in peer-reviewed print.

fiomet's pressure-sensing platform has been used and validated across independent research — including military-funded preclinical work.

CastLiner™ sensor and glowing F01 module on a large-animal subject during altitude testing
Air Force–funded · large-animal study

Proven durable in vivo — even at altitude.

Under an $850K U.S. Air Force RTAAC grant at the University of Cincinnati Medical Center, the CastLiner™ sensor was deployed in a large-animal model and remained durable and functional at 15,000 feet. It captured how negative-pressure wound therapy performance changes with altitude — data that, per fiomet, contributed to a change in the NPWT pump used by the military.1

Preclinical, large-animal research evaluating the fiomet sensor platform. It validates sensor durability and measurement, not CastLiner™ or DermaLiner™ as pressure-injury-prevention devices.
Peer-reviewed · 2020

fiomet's sensor in a published NPWT study

fiomet's flexible pressure sensor was used to measure surface pressures in a negative-pressure wound-therapy model, showing that wound-interface pressures vary meaningfully with depth and pump settings.

Rapp SJ et al. J Burn Care Res. 2020;41(1):104–112.
Peer-reviewed · 2022

A bioreactor for studying wound therapy

A second peer-reviewed paper describes a bioreactor for studying negative-pressure wound therapy on skin grafts, again employing fiomet's sensing approach.

Notorgiacomo, Rapp SJ et al. Int Wound J. 2022;19(3):633–642.
Dr. Scott Rapp with a young patient wearing a P-POD cranial orthotic
Dr. Scott Rapp, MD FACS · with a P-POD patient
Built by a surgeon

Inventor. Surgeon. Advocate for safer healing.

"This was never about invention. It was about prevention."

Dr. Rapp didn't just study wound healing — he lived it. A Stanford-trained cleft and craniofacial plastic surgeon, he is Chief of Plastic Surgery at Shriners Children's Ohio and leads the craniofacial program at Cincinnati Children's, treating complex cases across three children's hospitals. He created Fiomet to solve the pressure-related complications he saw in practice — including the kind of preventable, life-altering injury that can happen when no one can see the skin under a dressing.

It's not the team's first device to reach patients: Fiomet's founders previously brought P-POD — an FDA-cleared cranial orthotic for infants — from concept to point-of-care use.

"To me, real healing means never letting a hospital stay define the rest of someone's life."

Regulatory status

Anticipated Class I · 513(g) pending.

CastLiner™ and DermaLiner™ have not yet been cleared or approved by FDA; a 513(g) classification request is pending.4

Anticipated class
Class I
FDA status
513(g) pending
Use
Adjunct to clinical assessment
Get in touch

Bring early warning to your bedside.

See a live demo of CastLiner™ and DermaLiner™, the companion app, and EMR integration — and talk through a pilot for your unit.

Request a demo Email sales
sales@fiomet.com (513) 291-3323 Cincinnati, OH
Sources & references

The claims on this page, sourced.

Figures and statements throughout this site draw on the following Fiomet documentation and peer-reviewed literature. Epidemiology and clinical-threshold figures are cited to published clinical literature within Fiomet's background documentation.

  1. Fiomet, CastLiner™ Background & Significance (company document). Source for cast/splint epidemiology (≈ one application every 38 seconds; ~1.5 million per year; 10–28% complication rate; >$300 million in secondary U.S. costs; pediatric rates of ~8.9 and ~17.9 per 1,000), the ~32 mmHg / 2-hour tissue-ischemia threshold, sensor specifications (sensitivity from ~10 mmHg; <1 mm, fully wireless; antimicrobial silver-ink traces; ~30,000 data points/min), and the U.S. Air Force RTAAC large-animal / altitude study. These epidemiology and clinical figures are attributed within that document to published clinical literature.
  2. Rapp SJ, Dershem V, Zhang X, Schutte SC, Chariker ME. Varying Negative Pressure Wound Therapy Acute Effects on Human Split-Thickness Autografts. J Burn Care Res. 2020;41(1):104–112. Peer-reviewed study using Fiomet's pressure sensor.
  3. Notorgiacomo G, Rapp SJ, et al. A bioreactor for studying negative pressure wound therapy on skin grafts. Int Wound J. 2022;19(3):633–642. Peer-reviewed study employing Fiomet's sensing approach.
  4. CastLiner™ Instructions for Use, Fiomet Ventures, Inc. Source for device description, indications and contraindications, the blue/green/red status definitions, intended use as an adjunct to clinical assessment, anticipated Class I classification (513(g) pending), and non-sterile / intact-skin use.
  5. CastLiner™ & DermaLiner™ product literature, Fiomet Ventures, Inc. Source for remote-patient-monitoring workflow and CPT® codes 99453–99458, and pricing/reimbursement context. CPT® is a registered trademark of the American Medical Association.
  6. Fiomet, The Hidden Epidemic: Hospital-Acquired Pressure Injuries, Device-Related Complications & Market Opportunity (company research brief, v3, January 2026). Source for the reported-vs-estimated pressure-injury figures, drawing on published literature including Squitieri et al., “Success in Hospital-Acquired Pressure Ulcer Prevention: A Tale in Two Data Sets,” Health Affairs 2018 (administrative data captured ~1/20th of chart-review incidence — i.e. ~5% capture), and peer-reviewed meta-analyses finding medical device-related pressure injuries account for ~30–34.5% of all HAPIs. Reported figures (≈2.5 million cases; ~$26.8 billion) are the commonly cited U.S. totals; estimated true-incidence (~50 million) and burden ($500 billion+) are derived by applying published under-reporting multipliers and are presented as estimates.

Citations describe the basis for statements on this page and are provided for transparency; they are not an endorsement by the cited authors, journals, or agencies. CastLiner™ and DermaLiner™ have not been cleared or approved by FDA.